Formation of Research Committee Sample Clauses

Formation of Research Committee. The Research Committee will consist of an equal number of members from each of Taisho and Tularik, including any substitutions as may be needed from time to time, the chairperson of which will be one of the Tularik members. The parties shall notify each other in writing of the individuals who will act on such party's behalf as members of the Research Committee and of any changes in the membership thereof. All decisions of the Research Committee shall be unanimous.
Sample 1Sample 2Sample 3
AutoNDA by SimpleDocs
Formation of Research Committee. The Research Committee shall consist of an equal number of members from Dainippon and RiboGene, appointed and substituted by each party as necessary from time to time. Each member shall have appropriate technical credentials and knowledge and ongoing familiarity with the Research Program. The chairperson of the Research Committee shall be an employee of the party hosting the meeting. All decisions of the Research Committee shall be unanimous and shall be recorded in the minutes of the Research Committee.
Sample 1Sample 2Sample 3
Formation of Research Committee. The Research Committee shall consist of an equal number of members from Sumitomo and Tularik, appointed and substituted by each party as necessary from time to time. Each member shall have appropriate technical credentials and knowledge and ongoing familiarity with the Program. The Chairperson of the Research Committee shall be a Tularik employee appointed by the Research Committee. All decisions of the Research Committee shall be unanimous. To the extent that the members of the Research Committee are unable to reach a unanimous decision on an issue relating to an activity for which one party is primarily responsible under Appendix A, such party's appointed members shall finally decide the disputed issue.
Sample 1Sample 2Sample 3
Formation of Research Committee. The Research Committee shall consist of six (6) members, Merck and Tularik each to appoint and substitute as necessary from time to time three (3) members of such Committee. Each member shall have appropriate technical credentials and knowledge and ongoing familiarity with the Research Program. The Chairperson of the Research Committee shall be one of the Merck-appointed members. Except as otherwise provided in Sections 1.6, 1.8 and 1.32, all decisions of the Research Committee shall be unanimous.
Sample 1Sample 2Sample 3
Formation of Research Committee. Decision Making. Within ten (10) days after the Effective Date, the Parties shall establish a Research Committee having a total of four (4) members. The Research Committee shall have responsibility for strategic oversight of the Research Program and of implementation thereof. Gemini and CuraGen each shall select and have the right to replace up to two (2) representatives to serve as members of the Research Committee, each of whom shall have senior management responsibilities for the Party appointing such member. Either Party may designate a substitute committee member to participate in the event one of that Party's regular committee members is unable to be present at a meeting. The Research Committee shall meet, on every two months commencing from its formation, and from time to time during the term of this Agreement as otherwise agreed by the Parties. Regular meetings will alternate between New Haven, Connecticut, U.S.A. and Cambridge, England and any meeting may be held by teleconference or videoconference upon agreement of both parties. The Research Committee shall make decisions on the basis of unanimous consensus after a discussion of the matters as to which decisions are being made. In the event the Research Committee is unable to agree upon a particular matter, then such matter shall be submitted for resolution to an executive officer of each Party for resolution by good faith discussion. If such matter is not resolved by such officers within thirty (30) days of submission, then the matter will be submitted to an independent expert in the pharmaceutical or biotechnology (or other appropriate related) industry acting as an expert and not as an arbitrator, the identity of whom shall be agreed upon by the Research Committee (or failing such agreement, by two independent experts, where one such expert is identified and nominated by each of the Parties in their respective discretion) who shall resolve the matter by determining objectively what is the best course of action on a stand alone basis disregarding the individual subjective needs or preferences of the Parties. In the absence of manifest error, such determination shall be conclusive. Such matters are not subject to dispute resolution through arbitration or litigation under Article 11.
Sample 1
Formation of Research Committee. Decision Making ..................... 5 2.2 Conduct of Research Program .......................................... 5 2.3 Designation of Nominated Traits and Nominated Loci ................... 6 2.3 Research Responsibilities ............................................ 6 2.5
Sample 1
Formation of Research Committee. Decision Making. Within ten (10) days after the Effective Date, the Parties shall establish a Research Committee having a total of four (4) members. The Research Committee shall have responsibility for strategic oversight of the Research Program and the implementation thereof. Gemini and Celera each shall select and have the right to replace up to two (2) representatives to serve as members of the Research Committee, each of whom shall have senior management responsibilities for the Party appointing such member. Either Party may designate a substitute committee member to participate in the event one of the Party's regular committee members is unable to be present at a meeting. The Research Committee shall meet, on a bi-monthly basis commencing from its formation, and from time to time during the term of this Agreement as otherwise agreed by the Parties. The Research Committee shall make decisions on the basis of unanimous consensus after a discussion of the matters as to which decisions are being made.
Sample 1
AutoNDA by SimpleDocs

Related to Formation of Research Committee

  • Joint Research Committee The Parties hereby establish a committee to facilitate the Research Program as follows:

  • Research Committee 2.2.1 Establishment and Functions of the RC. -------------------------------------

  • Steering Committee Each Party shall name a mutually agreed upon equal number of representatives for the Steering Committee, which shall meet twice per calendar year, or as otherwise mutually agreed by the Parties. In the event that a Steering Committee dispute cannot be resolved, such dispute shall be escalated to a senior executive of each of Customer and Lonza. The primary function of the Steering Committee is to ensure the ongoing communication between the Parties and discuss and resolve any issues arising under this Agreement. In addition to the primary function described above, the Steering Committee shall also take on the following responsibilities:

  • Advisory Committee (a) The Partnership shall have a committee (the “Advisory Committee”) consisting of Fund Investors or their representatives or designees selected by the Managing General Partner; provided that no member of the Advisory Committee shall be an Affiliate of the Managing General Partner (or a designee or representative thereof). The Managing General Partner will meet with the Advisory Committee at least semi-annually to consult on various matters concerning the Partnership, including financial statements and appraisals, the status of existing investments and such other matters as the Managing General Partner may determine or any member of the Advisory Committee may reasonably propose.

  • Development Committee As soon as practicable, the Parties will establish a joint development committee, comprised of at least one (1) and up to two (2) representatives of Omega and at least one (1) and up to two (2) representatives of Acuitas (the “JDC”). One such representative from each Party will be such Party’s Workplan Leader. Each Party may replace its Workplan Leader and other JDC representatives at any time upon written notice to the other Party, provided, however, that each Party shall use reasonable efforts to ensure continuity on the JDC. With the consent of the other Party (which will not be unreasonably withheld, conditioned or delayed), each Party may invite non-voting employees and consultants to attend JDC meetings as necessary, subject to consultant’s agreement to be bound to the same extent as a permitted subcontractor under Section 3.1(i).

  • Joint Steering Committee [***] following the Effective Date [***], a joint steering committee (the “JSC”) will be established by the Parties to provide oversight and to facilitate information sharing between the Parties with respect to the activities under this Agreement.

  • Joint Development Committee The Parties shall form a joint development committee (the “Joint Development Committee” or “JDC”), made up of an equal number of representatives of Merck and BioLineRx, which shall have responsibility of coordinating all regulatory and other activities under, and pursuant to, this Agreement. Each Party shall designate a project manager (the “Project Manager”) who shall be responsible for implementing and coordinating activities, and facilitating the exchange of information between the Parties, with respect to the Study. Other JDC members will be agreed by both Parties. The JDC shall meet as soon as practicable after the Effective Date and then no less than twice yearly, and more often as reasonably considered necessary at the request of either Party, to provide an update on the progress of the Study. The JDC may meet in person or by means of teleconference, Internet conference, videoconference or other similar communications equipment. Prior to any such meeting, the BioLineRx Project Manager shall provide an update in writing to the Merck Project Manager, which update shall contain information about the overall progress of the Study, recruitment status, interim analysis (if results available), final analysis and other information relevant to the conduct of the Study. In addition to a Project Manager, each Party shall designate an alliance manager (the “Alliance Manager”), who shall endeavor to ensure clear and responsive communication between the Parties and the effective exchange of information, and shall serve as the primary point of contact for any issues arising under this Agreement. The Alliance Managers shall have the right to attend all JDC meetings and may bring to the attention of the JDC any matters or issues either of them reasonably believes should be discussed, and shall have such other responsibilities as the Parties may mutually agree in writing. In the event that an issue arises and the Alliance Managers cannot or do not, after good faith efforts, reach agreement on such issue, the issue shall be elevated to the Head of Clinical Oncology for Merck and the Vice President of Medical Affairs or Business Development for BioLineRx.

  • Joint Patent Committee (a) The Parties will establish a “

  • Operating Committee 7.01 To coordinate the operation of their respective generating, transmission and substation facilities, in order that the advantages to be derived hereunder may be realized by the parties hereto to the fullest practicable extent, the parties shall establish a committee of authorized representatives to be known as the Operating Committee. Each of the parties shall designate in writing delivered to the other party, the person who is to act as its representative on said committee (and the person or persons who may serve as alternates whenever such representative is unable to act). Each of such representatives and alternates shall be persons familiar with the generating, transmission, and substation facilities of the system of the party he represents, and each shall be fully authorized (1) to cooperate with the other representative (or alternates) and (2) to determine and agree from time to time, in accordance with this agreement and with any other relevant agreements then in effect between the parties, upon the following:

  • Joint Commercialization Committee As of the Effective Date, the Parties have established a joint commercialization committee (the “Joint Commercialization Committee” or the “JCC”), composed of up to [ * ] representatives of each Party, to monitor and discuss the Commercialization of Products at the operational level. Each JCC representative shall have knowledge and expertise in the commercialization of products similar to Products. The JCC shall in particular:

Time is Money Join Law Insider Premium to draft better contracts faster.